United States & Novo Nordisk
30 shared events · Importance 7 · Last updated Aug 15, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
United States: Key market for obesity drugs; pricing pressure and competition are central to the rivalry.
Novo Nordisk: Central player; shares up 35% from March low, launching oral Semaglutide and suing Lilly, but faces competition and past profit warnings.
Aug 03, 2026 · 6 articles
Domestic
United States: The U.S. government, through the VA, funds and conducts the trial, reflecting national investment in veteran health.
Novo Nordisk: Novo Nordisk's semaglutide is the drug being tested; positive results could expand its approved uses and market, though the trial is early-stage.
Jul 30, 2026 · 6 articles
Business
United States: The U.S. is a key market for GLP-1 drugs. The study's implications for presenteeism and productivity are relevant but require further validation.
Novo Nordisk: Novo Nordisk manufactures Ozempic and Wegovy, key GLP-1 drugs studied. Positive study results may support continued strong sales and market growth.
Jul 21, 2026 · 6 articles
Tech
United States: Country where the studies were conducted and where insurance coverage and regulatory approval decisions affect patient access to GLP-1 drugs for PMOS.
Novo Nordisk: Manufacturer of semaglutide, the GLP-1 drug tested in the PMOS trials; positive results could expand its approved indications and market.
Aug 15, 2026 · 12 articles
Tech
United States: U.S. regulators added a black box warning to Ozempic in June 2026 regarding thyroid cancer risk, and the FDA's stance is part of the regulatory context. The event may influence future regulatory decisions.
Novo Nordisk: As the manufacturer of Ozempic, Novo Nordisk is central to the debate. Positive observational studies could support sales, but expert caution and lack of randomized trial confirmation may limit upside. The company's stock may see volatility based on headlines.
Jul 13, 2026 · 6 articles
Business
United States: The event reflects U.S. healthcare and employment trends, with GLP-1 drugs becoming a significant cost factor for employers. It highlights the national debate over obesity treatment coverage and its economic implications.
Novo Nordisk: Novo Nordisk is a key manufacturer of GLP-1 drugs (Ozempic, Wegovy) covered by Bank of America. The bank's spending and broader employer adoption support Novo Nordisk's revenue growth, though pricing pressures remain.
Aug 05, 2026 · 6 articles
Tech
United States: The studies discussed involve patients and practices within the United States>>> and address a significant health concern for American women.
Novo Nordisk: Novo Nordisk>>> produces GLP-1 drugs like Wegovy, Ozempic, Rybelsus, Saxenda, and Victoza, which are showing potential benefits in cancer prevention and treatment.
Jun 02, 2026 · 45 articles
Tech
United States: Country where the study was conducted and where GLP-1 use is widespread.
Novo Nordisk: Manufacturer of semaglutide (Ozempic, Wegovy); study may raise safety concerns but risk is small.
Jul 14, 2026 · 6 articles
Domestic
United States: The United States>>> is the primary beneficiary of the TrumpRx program, with its citizens expected to save billions on prescription drug costs due to the 'most favored nation' policy and tariffs.
Novo Nordisk: Novo Nordisk>>> is participating in the TrumpRx program, agreeing to reduce prices on popular GLP-1 weight-loss medications.
Jun 06, 2026 · 8 articles
Business
United States: The US approved Awiqli earlier in 2026, contributing to its global rollout.
Novo Nordisk: Novo Nordisk launched Awiqli, its once-weekly insulin, in India, enhancing its product portfolio and competitive edge in the diabetes market.
Jul 09, 2026 · 21 articles
Regulatory
United States: The US previously approved Wegovy for MASH in August 2025, setting a precedent for the Indian approval.
Novo Nordisk: Novo Nordisk is the drug manufacturer; the approval expands Wegovy's indication in India, potentially increasing sales and market share in the obesity and metabolic disease market.
Jul 17, 2026 · 13 articles
Tech
United States: The study analyzed data from US adults, and the findings could have public health implications for the United States regarding violence prevention.
Novo Nordisk: Novo Nordisk manufactures Semaglutide and Semaglutide, and the study's findings could potentially broaden the market and perceived benefits of its GLP-1 medications.
Jun 17, 2026 · 6 articles
Business
United States: Key market; North American Cobalt Inc. sales fell 35.4% due to lenalidomide decline, impacting overall results.
Novo Nordisk: Novo Nordisk is the originator of semaglutide; the delay does not directly affect its products but may reduce competition in the short term.
Jul 09, 2026 · 23 articles
Business
United States: US leads efforts to curb high-tech exports to China, affecting ASML's sales; geopolitical risk.
Novo Nordisk: Novo Nordisk is compared as a European Union — European market cap peer; not directly impacted.
Jul 15, 2026 · 29 articles
Accidents
United States: US regulators may investigate the breach and enforce data protection laws, potentially imposing fines on Amgen.
Novo Nordisk: Mentioned as one of the healthcare companies recently affected by cyberattacks, highlighting sector-wide vulnerability.
Jul 31, 2026 · 6 articles
Business
Novo Nordisk: Novo Nordisk announced significant job cuts and a revised profit outlook due to increased competition and slowing sales of its key weight-loss and diabetes drugs. The company aims to simplify its structure and reallocate resources for future growth.
Sep 10, 2025 · 6 articles
Business
Novo Nordisk: Novo Nordisk partnered with Costco to expand access and sales of its GLP-1 medications, Semaglutide and Semaglutide, at a standardized discounted price, combating competition from compounding pharmacies.
Oct 03, 2025 · 8 articles
Regulatory
Novo Nordisk: Novo Nordisk agreed to lower prices for its obesity drug Wegovy, making it more accessible to United States — Medicare and United States — Medicaid recipients and those paying directly. The company's spokesperson declined to provide specific details on pricing changes.
Nov 06, 2025 · 6 articles
Tech
Novo Nordisk: Novo Nordisk produces Semaglutide and Semaglutide, which are GLP-1 agonist drugs. The research indicates that patients regain weight quickly after discontinuing these medications, potentially impacting long-term sales and cost-effectiveness assessments by health systems.
Jan 08, 2026 · 6 articles
Business
Novo Nordisk: Novo Nordisk launched its Wegovy pill in the United States, aiming to attract new consumers and regain market share in the competitive weight-loss drug market. This launch is expected to boost its fortunes after previous profit warnings and sliding shares.
Jan 05, 2026 · 7 articles
Regulatory
Novo Nordisk: Novo Nordisk received United States — Food and Drug Administration approval for its Wegovy pill, gaining an edge in the obesity treatment market over Eli Lilly and Company. The company expects the pill to be available within weeks, with a starting dose of $149 per month.
Dec 22, 2025 · 23 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States and Novo Nordisk interact across events, view sentiment trends, and discover connected entities.
Open Dashboard